Literature DB >> 12509689

Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women.

E Dogan1, C Posaci.   

Abstract

Biochemical markers of bone metabolism are divided into two groups: formation and resorption markers. Bone turnover is a dynamic process, which increases in postmenopausal period. Hormone replacement therapy (HRT) can diminish this increased bone turnover. Biochemical markers reflect acute changes in bone metabolism. Therefore, they may be very useful for the prediction of subsequent bone mineral density changes after HRT in menopausal women. Both oral and transdermal routes of HRT are efficacious in decreasing the levels of biochemical markers. However, markers do not replace bone mineral density measurement. Collagen type I cross linked N-telopeptide, collagen type I cross linked C-telopeptide, and osteocalcin are the most promising markers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12509689      PMCID: PMC1757944          DOI: 10.1136/pmj.78.926.727

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  26 in total

1.  Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.

Authors:  P Peris; L Alvarez; A Monegal; N Guañabens; M Durán; F Pons; M J Martínez de Osaba; M Echevarría; A M Ballesta; J Muñoz-Gómez
Journal:  Bone       Date:  1999-09       Impact factor: 4.398

2.  The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.

Authors:  R Marcus; L Holloway; B Wells; G Greendale; M K James; C Wasilauskas; J Kelaghan
Journal:  J Bone Miner Res       Date:  1999-09       Impact factor: 6.741

3.  Clinical usefulness of biochemical resorption markers in osteoporosis.

Authors:  P A Kyd; K De Vooght; F Kerkhoff; E Thomas; A Fairney
Journal:  Ann Clin Biochem       Date:  1999-07       Impact factor: 2.057

4.  Changes in bone collagen markers and in bone density in hormone treated and untreated postmenopausal women.

Authors:  M Brincat; R Galea; Y M Baron; A Xuereb
Journal:  Maturitas       Date:  1997-06       Impact factor: 4.342

5.  The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.

Authors:  C J Rosen; C H Chesnut; N J Mallinak
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

6.  Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells.

Authors:  R Pacifici; C Brown; E Puscheck; E Friedrich; E Slatopolsky; D Maggio; R McCracken; L V Avioli
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

7.  Biochemical markers of bone turnover during hormone replacement therapy.

Authors:  T Masahashi; Y Negoro; T Kuroki; M Asai; M Noguchi; M Nakanishi
Journal:  Int J Gynaecol Obstet       Date:  1999-02       Impact factor: 3.561

8.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.

Authors:  P Ravn; D Hosking; D Thompson; G Cizza; R D Wasnich; M McClung; A J Yates; N H Bjarnason; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

9.  Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.

Authors:  R Lindsay; F Cosman; R A Lobo; B W Walsh; S T Harris; J E Reagan; C L Liss; M E Melton; C A Byrnes
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

10.  Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.

Authors:  D Uebelhart; A Schlemmer; J S Johansen; E Gineyts; C Christiansen; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958

View more
  7 in total

1.  BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women.

Authors:  Vanita R Jagtap; Jayashri V Ganu; Nitin S Nagane
Journal:  Indian J Clin Biochem       Date:  2010-09-14

2.  Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.

Authors:  Yiyuan Zhang; Eryou Feng; Yang Xu; Wulian Wang; Tao Zhang; Lili Xiao; Rong Chen; Yu Lin; Dongdong Chen; Liqiong Lin; Kangyao Chen; Yanbin Lin
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women.

Authors:  Sudeepa Bhattacharyya; Eric R Siegel; Sara J Achenbach; Sundeep Khosla; Larry J Suva
Journal:  J Bone Miner Res       Date:  2008-07       Impact factor: 6.741

Review 5.  Ovariectomized rat model of osteoporosis: a practical guide.

Authors:  Nasibeh Yousefzadeh; Khosrow Kashfi; Sajad Jeddi; Asghar Ghasemi
Journal:  EXCLI J       Date:  2020-01-10       Impact factor: 4.068

6.  Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis.

Authors:  Saif Abdul-Majeed; Norazlina Mohamed; Ima-Nirwana Soelaiman
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-13       Impact factor: 2.629

7.  The Effects of Targeted Deliveries of Lovastatin and Tocotrienol on Ossification-Related Gene Expressions in Fracture Healing in an Osteoporosis Rat Model.

Authors:  Nurul 'Izzah Ibrahim; Norazlina Mohamed; Ima Nirwana Soelaiman; Ahmad Nazrun Shuid
Journal:  Int J Environ Res Public Health       Date:  2015-10-16       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.